Competitive Technologies, Inc. to Commercialize Intellectual Property for Stevens Institute of Technology.

FAIRFIELD, Conn. -- Competitive Technologies, Inc. (AMEX: CTT) today announced that it has signed an exclusive service and representation agreement with Stevens Institute of Technology to commercialize its intellectual property on a worldwide basis.

"We are pleased to enter into this relationship with Stevens Institute to serve their ongoing technology commercialization needs," said Ted Kutrumbos, CTT Business Development Executive. "The initial set of Stevens' IP includes among others, a novel, non-invasive bone mass measurement technique, stent delivery technologies, 3D imaging systems, and athletic devices."

Dr. Helena S. Wisniewski, Vice President, University Research and Enterprise Development for Stevens Institute of Technology, added, "We look forward to a growing relationship with CTT. Stevens' rich IP portfolio reflects our educational environment of enterprise and innovation - Technogenesis(R) - wherein students, and faculty nurture new technologies from concept to commercialization. We hope that our partnership with CTT will bring the university additional revenues which will help to continue our environment of innovation and enterprise."

"This and other new relationships are central to our growth strategy. As a leading research university, Stevens has some exciting technologies and we look forward to adding them to our portfolio and bringing them to market," commented Mike Kiley, CTT's Executive VP and Chief Technology Officer. "Stevens' technologies span multiple industries and include applications for life sciences, engineering and consumer products, among others."

About Stevens Institute of Technology

Founded in 1870 in Hoboken, NJ, Stevens is one of the leading technological universities in the country. Stevens offers baccalaureate, masters and doctoral degrees in engineering, science, computer science, management and technology management, as well as a baccalaureate in the humanities and liberal arts, and in business and technology. The university has enrollments of approximately 1,800 undergraduates and 2,700 graduate students. Additional information may be obtained from its web page at www.stevens.edu.

About Competitive Technologies, Inc.

Competitive Technologies, established in 1968, is a full service technology transfer and licensing provider, focusing on bringing the Intellectual Property assets of it clients to the marketplace. CTT specializes in identifying, developing and commercializing innovative technologies in a variety of areas including life and physical sciences, electronics, and nanotechnologies. Through its global distribution platform, CTT maximizes the value of its clients' intellectual assets. For more information, please visit: www.competitivetech.net.

Statements about our future expectations, including development and regulatory plans, and all other statements in this press release, other than historical facts, are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. If and when used herein, the words "may," "will," "should," "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions, as they relate to us or our business or management, are intended to identify such forward-looking statements. These statements involve risks and uncertainties related to market acceptance of and competition for our licensed technologies, growth strategies, operating performance, industry trends, and other risks and uncertainties inherent in our business, including those set forth in Item 7 under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended July 31, 2005, filed with the Securities and Exchange Commission ("SEC") on October 13, 2005, and other factors that may be described in our other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.